A novel strategy using g-csf to support ema/co for high-risk gestational trophoblastic disease

Ellen M. Hartenbach, Andrew K. Saltzman, Jonathan R. Carter, Leo B. Twiggs

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.

Original languageEnglish (US)
Pages (from-to)105-108
Number of pages4
JournalGynecologic oncology
Volume56
Issue number1
DOIs
StatePublished - Jan 1995

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'A novel strategy using g-csf to support ema/co for high-risk gestational trophoblastic disease'. Together they form a unique fingerprint.

  • Cite this